380 related articles for article (PubMed ID: 16041052)
1. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.
Glynn A; Roy CJ; Powell BS; Adamovicz JJ; Freytag LC; Clements JD
Infect Immun; 2005 Aug; 73(8):5256-61. PubMed ID: 16041052
[TBL] [Abstract][Full Text] [Related]
2. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
[TBL] [Abstract][Full Text] [Related]
3. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
[TBL] [Abstract][Full Text] [Related]
4. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
5. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen.
Garmory HS; Freeman D; Brown KA; Titball RW
Vaccine; 2004 Feb; 22(8):947-57. PubMed ID: 15161071
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
7. Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.
Gallagher TB; Mellado-Sanchez G; Jorgensen AL; Moore S; Nataro JP; Pasetti MF; Baillie LW
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007644. PubMed ID: 31430284
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
Jones T; Adamovicz JJ; Cyr SL; Bolt CR; Bellerose N; Pitt LM; Lowell GH; Burt DS
Vaccine; 2006 Mar; 24(10):1625-32. PubMed ID: 16243411
[TBL] [Abstract][Full Text] [Related]
9. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice.
Morton M; Garmory HS; Perkins SD; O'Dowd AM; Griffin KF; Turner AK; Bennett AM; Titball RW
Vaccine; 2004 Jun; 22(20):2524-32. PubMed ID: 15193377
[TBL] [Abstract][Full Text] [Related]
10. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
Tripathi V; Chitralekha KT; Bakshi AR; Tomar D; Deshmukh RA; Baig MA; Rao DN
Vaccine; 2006 Apr; 24(16):3279-89. PubMed ID: 16476510
[TBL] [Abstract][Full Text] [Related]
11. The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses.
Elvin SJ; Williamson ED
Microb Pathog; 2000 Oct; 29(4):223-30. PubMed ID: 10993741
[No Abstract] [Full Text] [Related]
12. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague.
Leary SE; Griffin KF; Galyov EE; Hewer J; Williamson ED; Holmström A; Forsberg A; Titball RW
Microb Pathog; 1999 Mar; 26(3):159-69. PubMed ID: 10089156
[TBL] [Abstract][Full Text] [Related]
13. Small protective fragments of the Yersinia pestis V antigen.
Vernazza C; Lingard B; Flick-Smith HC; Baillie LW; Hill J; Atkins HS
Vaccine; 2009 May; 27(21):2775-80. PubMed ID: 19366573
[TBL] [Abstract][Full Text] [Related]
14. Prospects for new plague vaccines.
Feodorova VA; Corbel MJ
Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
[TBL] [Abstract][Full Text] [Related]
16. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
Powell BS; Andrews GP; Enama JT; Jendrek S; Bolt C; Worsham P; Pullen JK; Ribot W; Hines H; Smith L; Heath DG; Adamovicz JJ
Biotechnol Prog; 2005; 21(5):1490-510. PubMed ID: 16209555
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
[TBL] [Abstract][Full Text] [Related]
18. Immunisation against plague by transcutaneous and intradermal application of subunit antigens.
Eyles JE; Elvin SJ; Westwood A; Lebutt CS; Alpar HO; Somavarapu S; Williamson ED
Vaccine; 2004 Oct; 22(31-32):4365-73. PubMed ID: 15474730
[TBL] [Abstract][Full Text] [Related]
19. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine.
Elvin SJ; Eyles JE; Howard KA; Ravichandran E; Somavarappu S; Alpar HO; Williamson ED
Vaccine; 2006 May; 24(20):4433-9. PubMed ID: 16546306
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J
Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
